Clinical Trial VICCPHI1248

Title

An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC0032 in Patients with Locally Advanced or Metastatic Solid Tumors and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

Principal Investigator(s)

Ingrid Mayer

Details

  • Protocol No. VICCPHI1248
  • Open Date: 10/12/2012
  • Staging: Phase I
  • Age Group: Adults
  • Scope: National
  • Objective: - To evaluate the safety and tolerability of daily administration of GDC-0032 - To evaluate the safety and tolerability of concomitant daily administration of GDC-0032 and letrozole in postmenopausal female patients with locally advanced or metastatic hormone receptor-positive breast cancer - To evaluate the safety and tolerability of concomitant daily administration of GDC-0032 and fulvestrant in postmenopausal female
  • Disease Sites: Breast; Phase I
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Fulvestrant; GDC-0032; Letrozole (Femara); Midazolam
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01296555
  • Secondary Protocol No: PMT4979g

Description

Eligibility

Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.